Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.

This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.

In this report, a patient with vitiligo and systemic lupus erythematosus achieved complete skin repigmentation after 30 days of treatment with the oral JAK inhibitor tofacitinib, with no adverse reactions, suggesting its efficacy and safety as a potential treatment for vitiligo with coexisting autoimmune conditions.

This study found that patients with rheumatoid arthritis taking tofacitinib had higher rates of serious adverse events compared to those with alopecia areata, highlighting the need for careful assessment when using it off-label for alopecia areata.

This case report found that oral tofacitinib treatment resulted in more than 90% hair regrowth in a 6-year-old with severe alopecia areata, with no relapse after dose reduction.

In this study, pediatric patients with alopecia areata treated with systemic tofacitinib showed significant improvement at 12 months, but the small sample size and retrospective design limit conclusions about its effectiveness.

This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.

This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.

This retrospective cohort study reported that oral tofacitinib was effective in treating alopecia areata, with 83.2% of patients showing improvement and 16.0% achieving complete remission. Earlier intervention and previous hair regrowth were linked to better outcomes, and no severe adverse events were observed.

In this study, tofacitinib treatment significantly reduced hair loss on the head and body, as well as nail involvement, in patients with alopecia areata over 18 months, with minimal side effects reported.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

This case report presented the successful treatment of a patient with alopecia universalis using tofacitinib.

This study observed that oral tofacitinib was effective and safe for treating alopecia areata in paediatric patients, with 82% of pre-adolescent participants experiencing hair regrowth and 64% showing significant improvement in their hair loss severity scores.

This study found that a topical gel containing Minoxidil and Tofacitinib citrate showed promise for treating alopecia areata, with formulation F5 demonstrating effective drug release and stability in evaluations.

This case report describes a successful treatment of alopecia universalis in a 37-year-old female using oral tofacitinib, along with other therapies, resulting in significant hair regrowth without notable safety concerns.

This study found that 23.2% of surveyed dermatologists in Saudi Arabia prescribe Tofacitinib for alopecia areata, with 72.4% reporting its effectiveness, while 47.7% cited unavailability as the main reason for not prescribing.

This case report details the successful use of oral tofacitinib for six months, which led to significant hair regrowth in an adult male Indian patient with extensive and refractory alopecia areata, highlighting tofacitinib's potential in managing resistant cases within this population.

In this case report, the researchers described the use of tofacitinib in treating a 14-year-old boy from India with severe alopecia areata, achieving complete hair regrowth within 2 months without serious adverse events, highlighting tofacitinib's potential benefits and safety in adolescent cases.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

In this study, tofacitinib treatment for six months significantly reduced hair loss severity in alopecia areata patients.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This study found that Tofacitinib effectively improved hair regrowth in patients with Alopecia Areata, with most participants showing a significant change in their Severity of Alopecia Tool scores.

In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.

In this clinical trial, Tofacitinib effectively promoted hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis, with 75.6% experiencing no side effects, making it a promising treatment option according to the study.

In this case report, a 42-year-old woman with cutaneous dermatomyositis showed significant improvement, including reduction of erythema, pruritus, and scaling, after starting JAK inhibitor tofacitinib, especially when conventional systemic treatments failed and intravenous immune globulin wasn't viable.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

This case report describes a young Indian boy with resistant alopecia areata who experienced nearly complete hair regrowth within 5 months of treatment with oral tofacitinib.

This report describes a case of alopecia universalis successfully treated with tofacitinib, though it was associated with increased peripheral blood cytokine levels.